Advances in clinical application of cryoablation therapy for hepatocellular carcinoma and metastatic liver tumor

Journal of Clinical Gastroenterology

Volumn 48, Issue 10, 2014, Pages 830-836

  Hu, Ke Qin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ablation therapy; Cryoablation; Cryotherapy; Efficacy; Hepatocellular carcinoma (HCC); Image guided tumor ablation; Safety

Indexed keywords

SORAFENIB;

ABLATION DEVICE; BILE DUCT INJURY; BLEEDING; CANCER PROGNOSIS; CANCER SURGERY; CANCER THERAPY; CRYOABLATION; CRYOSHOCK; DIGESTIVE SYSTEM FISTULA; GALLBLADDER DISEASE; GALLBLADDER FISTULA; HISTORY OF MEDICINE; HUMAN; IATROGENIC DISEASE; INTERMETHOD COMPARISON; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; PATIENT SAFETY; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; REVIEW; TUMOR SEEDING; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CRYOSURGERY; DEVICES; EQUIPMENT DESIGN; HISTORY; LIVER NEOPLASMS; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CRYOSURGERY; EQUIPMENT DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIVER NEOPLASMS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84916238834     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/mcg.0000000000000201     Document Type: Review

References (57)

1. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56: 908-943.
2. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52: 762-773.
3. Sheen AJ, Siriwardena AK. The end of cryotherapy for the treatment of nonresectable hepatic tumors? Ann Surg Oncol. 2005;12: 202-204.
4. Hutchinson M, Shyn P, Silverman S. Cryoablation of liver tumors. In: Dupuy DE, Fong Y, McMullen WN, eds. Image-Guided Cancer Therapy. New York: Springer; 2013: 491-503.
5. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;7: CD007611.
6. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180: 1993-2004.
7. Wang C, Lu Y, Chen Y, et al. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: A prospective study. Clin Exp Metastasis. 2009;26: 839-848.
8. Wong WS, Patel SC, Cruz FS, et al. Cryosurgery as a treatment for advanced stage hepatocellular carcinoma. Cancer. 1998;82: 1268-1278.
9. Chen HW, Lai EC, Zhen ZJ, et al. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg. 2011;9: 188-191.
10. Yang YP, Wang CP, Lu YY, et al. Outcomes of ultrasoundguided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19: 674-684.
11. Ng KM, Chua TC, Saxena A, et al. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol. 2012;19: 1276-1283.
12. Manenti G, Perretta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: Clinical experience and preliminary results of cryotherapy. Eur Radiol. 2011;21: 2344-2353.
13. Shelley M, Wilt TJ, Coles B, et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 2007; CD005010.
14. Niu L, Chen J, Yao F, et al. Percutaneous cryoablation for stage IV lung cancer: A retrospective analysis. Cryobiology. 2013;67: 151-155.
15. Inoue M, Nakatsuka S, Yashiro H, et al. Percutaneous cryoablation of lung tumors: Feasibility and safety. J Vasc Interv Radiol. 2012;23: 295-302.
16. El Dib R, Touma NJ, Kapoor A. Cryoablation vs. radiofrequency ablation for the treatment of renal cell carcinoma: A meta-analysis of case series studies. BJU Int. 2012;110: 510-516.
17. Erinjeri JP, Clark TW. Cryoablation: Mechanism of action and devices. J Vasc Interv Radiol. 2010;21: S187-S191.
18. Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort study. Hepatology. 2011;53: 136-147.
19. Lin SM, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54: 1151-1156.
20. OgiharaM,Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: Long-term outcomes. HPB (Oxford). 2005;7: 214-221.
21. Hinshaw JL, Lee FT Jr. Cryoablation for liver cancer. Tech Vasc Interv Radiol. 2007;10: 47-57.
22. Wong J, Lee KF, Lee PS, et al. Radiofrequency ablation for 110 malignant liver tumors: Preliminary results on percutaneous and surgical approaches. Asian J Surg. 2009;32: 13-20.
23. Wang C, Wang H, Qu J, et al. Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma. World J Gastroenterol. 2012;18: 6587-6596.
24. Livraghi T, Lazzaroni S, Meloni F, et al. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005;92: 856-858.
25. Pearson AS, Izzo F, Fleming R, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178: 592-598.
26. Tait I, Yong S, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg. 2002;89: 1613-1619.
27. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm. Arch Surgery. 2000;135: 657-664.
28. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002;137: 1332-1339.
29. Dunne RM, Shyn PB, Sung JC, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: A comparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol. 2014;83: 632-638.
30. Sabel MS. Cryo-immunology: A review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58: 1-11.
31. Rubinsky B. Cryosurgery. Annu Rev Biomed Eng. 2000;2: 157-187.
32. Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95: 1187-1191.
33. Rupp CC, Hoffmann NE, Schmidlin FR, et al. Cryosurgical changes in the porcine kidney: Histologic analysis with thermal history correlation. Cryobiology. 2002;45: 167-182.
34. Kimura M, Rabbani Z, Mouraviev V, et al. Morphology of hypoxia following cryoablation in a prostate cancer murine model: Its relationship to necrosis, apoptosis and, microvessel density. Cryobiology. 2010;619: 148-154.
35. Bhardwaj N, Gravante G, Strickland AD, et al. Cryotherapy of the liver: A histological review. Cryobiology. 2010;61: 1-9.
36. Zhou L, Wang CP, Lu YY, et al. Decrease in size of nontreated lesions after cryoablation for hepatocellular carcinoma. Hepatogastroenterology. 2012;59: 252-254.
37. Osada S, Imai H, Tomita H, et al. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol. 2007;95: 491-498.
38. Zhou L, Fu JL, Lu YY, et al. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virusrelated hepatocellular carcinoma. J Gastroenterol. 2010;45: 968-978.
39. Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PDL1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6: E23621.
40. Yang WL, Addona T, Nair DG, et al. Apoptosis induced by cryo-injury in human colorectal cancer cells is associated with mitochondrial dysfunction. Int J Cancer. 2003;103: 360-369.
41. Baust JG, Gage AA, Clarke D, et al. Cryosurgery-A putative approach to molecular based optimization. Cryobiology. 2004;48: 190-204.
42. Klossner DP, Baust JM, VanBuskirk RG, et al. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. BJU Int. 2008;101: 1310-1316.
43. Clarke DM, Robilotto AT, VanBuskirk RG, et al. Targeted induction of apoptosis via TRAIL and cryoablation: A novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10: 175-184.
44. Qiu JL, Huang PZ, Liu Q, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9: 166-175.
45. Qu JH, Chang XJ, Lu YY, et al. Overexpression of metastasisassociated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2012;18: 2995-3003.
46. Yang YP, Qu JH, Chang XJ, et al. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11: 41-54.
47. Orlacchio A, Bazzocchi G, Pastorelli D, et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: Initial experience. Cardiovasc Intervent Radiol. 2008;31: 587-594.
48. Shimizu T, Sakuhara Y, Abo D, et al. Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16: 816-823.
49. Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12: 616-628.
50. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359: 378-390.
51. Yang Y, Lu Y, Wang C, et al. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63: 159-169.
52. Kerkar S, Carlin AM, Sohn RL, et al. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004;136: 770-779.
53. Shock SA, Laeseke PF, Sampson LA, et al. Hepatic hemorrhage caused by percutaneous tumor ablation: Radiofrequency ablation versus cryoablation in a porcine model. Radiology. 2005;236: 125-131.
54. Bagia JS, Perera DS, Morris DL. Renal impairment in hepatic cryotherapy. Cryobiology. 1998;36: 263-267.
55. Seifert JK, Stewart GJ, Hewitt PM, et al. Interleukin-6 and tumor necrosis factor-alpha levels following hepatic cryotherapy: Association with volume and duration of freezing. World J Surg. 1999;23: 1019-1026.
56. Wang C, Yang Y. Percutaneous argon-helium cryoablation for hepatocellular carcinoma: Safety and efficacy. Infect Dis Info. 2012;25: 312-316.
57. Liu Z, Ahmed M, Weinstein Y, et al. Characterization of the RF ablation-induced "oven effect": The importance of background tissue thermal conductivity on tissue heating. Int J Hyperthermia. 2006;22: 327-342.